Vol. 5 No. 11 (2025)
Reimbursement Reviews

Ibrutinib

decorative image of the issue cover

Published November 3, 2025

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses Ibrutinib (Imbruvica), 560 mg daily.
  • Indication under consideration for reimbursement: In combination with immunochemotherapy with or without ASCT in the treatment of previously untreated transplant-eligible patients with MCL.